XML 17 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
Net revenue $ 464,662 $ 404,642 $ 963,195 $ 850,762
Cost of goods sold 319,666 296,381 633,244 606,124
Cost of goods sold impairment charges 759 3,012 2,215 56,309
Gross profit 144,237 105,249 327,736 188,329
Selling, general and administrative 80,944 67,281 158,920 151,717
Research and development 45,572 48,016 81,951 101,874
In-process research and development impairment charges 0 0 960 22,787
Intellectual property legal development expenses 3,550 2,511 4,820 6,677
Acquisition, transaction-related and integration expenses 1,787 3,519 4,362 9,551
Charges (gains) related to legal matters, net 1,300 0 5,800 0
Restructuring and other charges 333 2,835 2,381 8,996
Operating income (loss) 10,751 (18,913) 68,542 (113,273)
Other (expense) income:        
Interest expense, net (36,669) (43,886) (76,568) (87,167)
Foreign exchange gain (loss), net 3,466 8,311 (1,715) 2,847
Gain (loss) on sale of international businesses, net 123 (1,888) 123 6,930
Other income, net 571 149 1,204 1,256
Total other expense, net (32,509) (37,314) (76,956) (76,134)
Loss before income taxes (21,758) (56,227) (8,414) (189,407)
Provision for (benefit from) income taxes 2,186 (5,701) (105,987) (14,129)
Net (loss) income (23,944) (50,526) 97,573 (175,278)
Less: Net loss attributable to non-controlling interests 11,948 33,624 5,498 110,495
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (11,996) $ (16,902) $ 103,071 $ (64,783)
Net (loss) earnings per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders:        
Class A and Class B-1 basic (in usd per share) $ (0.08) $ (0.13) $ 0.70 $ (0.51)
Class A and Class B-1 diluted (in usd per share) $ (0.08) $ (0.13) $ 0.69 $ (0.51)
Weighted-average common shares outstanding:        
Class A and Class B-1 basic (in shares) 147,392 128,016 147,286 127,852
Class A and Class B-1 diluted (in shares) 147,392 128,016 148,309 127,852